Oncology

  • 25 July 2019
    News

    BMS’ Opdivo fails to meet primary endpoint in NSCLC

    Bristol-Myers Squibb (BMS) has announced that its immunotherapy Opvido (nivolumab) plus chemotherapy failed to meet its primary endpoint of overall survival (OS) in the Phase III CheckMate-227 trial of patients...

  • 19 July 2019
    News

    UK’s NICE backs Novartis breast cancer drug Kisqali

    The UK’s National Institute for Health and Care Excellence (NICE) has approved Novartis’ drug Kisqali (ribociclib) in combination with fulvestrant for the treatment of certain patients with advanced breast cancer.

Close
Close
Close

Go Top